SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard who wrote (66)9/7/1997 10:53:00 AM
From: chirodoc   of 569
 
<<. Genzyme alienated the orthopaedic community >> what did they do?

<<For most patients THREE procedures are necessary. One ... for diagnosis ( hard to make by MRI or before surgery. Two ... for biopsy and three for implantation. Many patients are nor willing to undergo that many procedures.>>

Is it possible diagnosis could EVENTUALLY be done with MR only?

And, could biopsy eventually be done on the ear, or some other simple area to access? or does it need to be done on the knee?

Lastly is it possible that the surgery could eventually be done using arthrosopic procedures--simplifying everything?

Sorry for all these questions, but carticel and synvisc could eventually be competitiors OR COMPLEMENTARY procedures--synvisc initially and then carticel when there is insufficient results. they both have good long term outlooks as stocks imho, but synvisc looks much better in the short term.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News